Loading company…
Pheast Therapeutics develops cancer immunotherapies targeting innate immune checkpoints.
Founded in 2020 by Amira Barkal and based in California, Pheast Therapeutics develops checkpoint therapies that target the innate immune system to treat cancer. Its work includes CD47 and CD24 programs for blood cancers and solid tumors. The company raised USD 76 million in Series A funding in April 2022, co-led by ARCH Venture Partners and Catalio Capital Management, with Alexandria Venture Investments and Risk and Reward Group participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in